These findings suggest that engineered DCs play a crucial role in enhancing the infiltration of cytotoxic CD8+ T cells into pancreatic tumors, potentially contributing to improved anti-tumor immunity. This evidence concerns the gene CD8A and pancreatic neoplasm.